Shattuck Labs presents preclinical data at 2023 AACR meeting

Shattuck Labs announced preclinical data at the 2023 American Association for Cancer Research, AACR, Annual Meeting in Orlando, Florida, from the company’s GADLEN platform. "We are pleased to share pre-clinical data demonstrating that the CD20-targeted GADLEN efficiently directs small numbers of human Vgamma9Vdelta2 T cells to serially kill greater than 99% of human B cells in a humanized mouse model," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. "These data led to the first study of a GADLEN compound in non-human primates, where once again treatment with a CD20-targeted GADLEN directed low frequencies of endogenous Vgamma9Vdelta2 T cells to eliminate CD20 positive B cells with a rapid kinetic. Importantly, the GADLEN compound was well tolerated in non-human primates up to the highest administered dose of 25 mg/kg, without evidence of cytokine release syndrome or other toxicities, potentially providing differentiation from CD3-directed T cell engagers. These data underlie our enthusiasm to advance a GADLEN product candidate into the clinic designed for the treatment of antibody-mediated autoimmune diseases." Details of the presentations are as follows: Abstract title: Rapid Serial Killing of Target Cells by Vgamma9Vdelta2 T Cells in Cynomolgus Macaques and Humanized Mice Treated with a CD20-Directed Heterodimeric Butyrophilin 2A1/3A1 Fusion Protein